UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

February 17, 2009

 

Commission File Number:0001284823

 


 

XYRATEX LTD

(Translation of registrant’s name into English)

 

Langstone Road,

Havant

PO9 1SA

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or 40-F.

Form 20-F   x      Form 40-F    o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)   o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes   o      No   x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

 

 

 



 

FOR IMMEDIATE RELEASE

 

Xyratex Ltd Announces Final Results for the Fourth Quarter and Fiscal Year 2008

 

Havant, UK, February 17, 2009—Xyratex Ltd (Nasdaq: XRTX), a leading provider of enterprise class data storage subsystems and storage process technology, today announced final results for the fourth quarter and fiscal year ended November 30, 2008. These results represent an update to the preliminary results announced on January 6, 2009.

 

The only change from the results announced on January 6 is related to the specific provision representing inventory and future vendor claims. This provision was associated with a specific Networked Storage Solutions customer  product forecast which indicated a transition to an updated version sooner than originally planned, giving rise to an exposure on long lead time components. Within its preliminary results the Company provided what it believed would be its maximum probable exposure of $9.5 million.

 

Following a thorough assessment of the exposure and mitigation opportunities, it has been concluded that the total provision required is $2 million and hence the Company has been able to write back $7.5 million of the preliminary provision.

 

The updated and final results for Xyratex Ltd for the fourth quarter and fiscal year ended November 30, 2008 are summarized below:

 

·                  Revenues for the fourth quarter were $285.4 million, an increase of 15.1% compared to revenues of $248 million for the same period last year. Revenues for the full year were $1,049.7 million, an increase of 12.7%, compared to revenues of $931.6 million for fiscal year 2007.

·                  Fourth quarter GAAP net loss was $55.7 million, or $1.92 per diluted share compared to GAAP net income of $11.7 million in the same period last year.

·                  A GAAP net loss for fiscal year 2008 of $47.9 million, or $1.64 per diluted share compared to a GAAP net income of $28.1 million for fiscal year 2007.

·                  Fourth quarter non-GAAP net income of $0.4 million, or $0.02 per diluted share compared to non-GAAP net income of $13.1 million in the same quarter a year ago.

·                  A non-GAAP net income for fiscal year 2008 of $16.2 million, or a diluted earnings per share of $0.56 compared to non-GAAP net income of $37.5 million, or $1.26 per diluted share, for fiscal year 2007(1).

·                  Gross profit margin in the fourth quarter of 12.5%, compared to 18.5% in the same period last year and 17.6% in the prior quarter.

 

These results will be reflected in the Company’s Annual Report on Form 20-F to be issued shortly.

 

2



 


(1) Non-GAAP net income (loss) and diluted earnings (loss) per share excludes (a) amortization of intangible assets, (b) equity compensation expense, (c) specified non-recurring or non-cash items, such as the impairment of goodwill and the valuation allowance against a deferred tax asset, and (d) the related tax effects. Reconciliation of non-GAAP net income and diluted earnings per share to GAAP net income and GAAP diluted earnings per share is included in a table immediately following the condensed consolidated statements of cash flow below.

 

The intention in providing these non-GAAP measures is to provide supplemental information regarding the Company’s operational performance whilst recognizing that they have material limitations and that they should only be referred to with reference to the corresponding GAAP measure.

 

The Company believes that the provision of these non-GAAP financial measures is useful to investors and investment analysts because it enables comparison to the Company’s historical operating results, those of competitors and other industry participants and also provides transparency to the measures used by management in operational and financial decision making. In relation to the specific items excluded: (a) intangible assets represent costs incurred by the acquired business prior to acquisition, are not cash costs and will not be replaced when the assets are fully amortized and therefore the exclusion of these costs provides management and investors with better visibility of the costs required to generate revenue over time; (b) equity compensation expense is non-cash in nature, is outside the control of management during the period in which the expense is incurred and in addition has not been measured consistently as a result of the implementation of FAS 123R; (c) the impairment of goodwill and the valuation allowance against the deferred tax asset is non-recurring,  non-cash and is not comparable across periods or with other companies; (d) the exclusion of the related tax effects of excluding items (a) to (c) is necessary to show the effect on net income of the change in tax expense that would have been recorded if these items had not been incurred.

 

Safe Harbor Statement

 

This press release contains forward—looking statements. These statements relate to future events or our future financial performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate, failure to retain key employees, changes in our customers volume requirements, cancellation or delay of projects and adverse general economic conditions in the United States and internationally. These risks and other factors include those listed under “Risk Factors” and elsewhere in our

 

3



 

Annual Report on Form 20-F as filed with the Securities and Exchange Commission (File No. 000-50799). In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

About Xyratex

 

Xyratex is a leading provider of enterprise class data storage subsystems and storage process technology. The company designs and manufactures enabling technology that provides OEM and disk drive manufacturers with data storage products to support high-performance storage and data communication networks. Xyratex has over 20 years of experience in research and development relating to disk drives, storage systems and high-speed communication protocols.

 

Founded in 1994 in an MBO from IBM, and with headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in Europe, the United States and South East Asia.

 

For more information, visit www.xyratex.com.

 

Contacts:

 

Xyratex Investor Relations

Brad Driver, +1 408-325-7260

bdriver@us.xyratex.com

www.xyratex.com

 

4



 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

Three Months Ended,

 

Year Ended

 

 

 

November 30,

 

November 30,

 

November 30,

 

November 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

 

 

 

 

(US dollars in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

Networked Storage Solutions

 

$

222,300

 

$

187,216

 

$

855,770

 

$

693,990

 

Storage Infrastructure

 

63,127

 

60,772

 

193,946

 

237,643

 

Total revenues

 

285,427

 

247,988

 

1,049,716

 

931,633

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

249,827

 

202,133

 

891,139

 

762,582

 

Gross profit:

 

 

 

 

 

 

 

 

 

Networked Storage Solutions

 

18,643

 

28,165

 

107,275

 

100,573

 

Storage Infrastructure

 

17,234

 

18,046

 

52,566

 

69,716

 

Equity compensation

 

(277

)

(356

)

(1,264

)

(1,238

)

Total gross profit

 

35,600

 

45,855

 

158,577

 

169,051

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

22,726

 

19,370

 

85,897

 

77,559

 

Selling, general and administrative

 

15,984

 

16,532

 

63,686

 

61,977

 

Amortization of intangible assets

 

1,223

 

2,485

 

4,882

 

7,304

 

Impairment of goodwill

 

34,256

 

 

34,256

 

 

Total operating expenses

 

74,189

 

38,387

 

188,721

 

146,840

 

Operating income (loss)

 

(38,589

)

7,468

 

(30,144

)

22,211

 

Other income

 

 

 

 

890

 

Interest income, net

 

166

 

1,030

 

1,618

 

3,283

 

Income (loss) before income taxes

 

(38,423

)

8,498

 

(28,526

)

26,384

 

Provision (benefit) for income taxes

 

17,324

 

(3,229

)

19,383

 

(1,725

)

Net income (loss)

 

$

(55,747

)

$

11,727

 

$

(47,909

)

$

28,109

 

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

 

$

(1.92

)

$

0.40

 

$

(1.64

)

$

0.97

 

Diluted

 

$

(1.92

)

$

0.39

 

$

(1.64

)

$

0.94

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares (in thousands), used in computing net earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

 

29,096

 

29,100

 

29,157

 

28,985

 

Diluted

 

29,096

 

29,758

 

29,157

 

29,866

 

 

5



 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

November 30,

 

November 30,

 

 

 

2008

 

2007

 

 

 

(US dollars and amounts in
thousands)

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

28,013

 

$

70,678

 

Accounts receivable, net

 

140,879

 

122,327

 

Inventories

 

128,183

 

91,662

 

Prepaid expenses

 

2,746

 

2,994

 

Deferred income taxes

 

1,000

 

3,000

 

Other current assets

 

4,430

 

8,275

 

Total current assets

 

305,251

 

298,936

 

Property, plant and equipment, net

 

47,229

 

37,421

 

Intangible assets, net

 

11,162

 

54,175

 

Deferred income taxes

 

9,545

 

19,743

 

Total assets

 

$

373,187

 

$

410,275

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

111,295

 

$

96,046

 

Employee compensation and benefits payable

 

9,745

 

13,280

 

Deferred revenue

 

8,386

 

15,212

 

Income taxes payable

 

2,573

 

1,165

 

Other accrued liabilities

 

27,599

 

11,311

 

Total current liabilities

 

159,598

 

137,014

 

Long-term debt

 

 

 

Total liabilities

 

159,598

 

137,014

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

Common shares of Xyratex Ltd (in thousands), par value $0.01 per share 70,000 authorized, 29,146 and 29,117 issued and outstanding

 

291

 

291

 

Additional paid-in capital

 

366,067

 

356,268

 

Accumulated other comprehensive income

 

(13,603

)

1,847

 

Accumulated deficit

 

(139,166

)

(85,145

)

Total shareholders’ equity

 

213,589

 

273,261

 

Total liabilities and shareholders’ equity

 

$

373,187

 

$

410,275

 

 

6



 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

Year Ended

 

 

 

November 30,

 

November 30,

 

 

 

2008

 

2007

 

 

 

(US dollars in thousands)

 

Cash flows from operating activities:

 

 

 

 

 

Net income (loss)

 

$

(47,909

)

$

28,109

 

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation

 

15,770

 

13,683

 

Amortization of intangible assets

 

4,882

 

7,304

 

Impairment of intangible assets

 

34,256

 

 

Non-cash equity compensation

 

7,646

 

8,057

 

Loss on sale of assets

 

185

 

341

 

Changes in assets and liabilities, net of impact of acquisitions and divestitures

 

 

 

 

 

Accounts receivable

 

(18,552

)

(17,003

)

Inventories

 

(36,521

)

1,449

 

Prepaid expenses and other current assets

 

1,455

 

(2,956

)

Accounts payable

 

15,249

 

11,150

 

Employee compensation and benefits payable

 

(3,535

)

(3,365

)

Deferred revenue

 

(6,826

)

(1,091

)

Income taxes payable

 

1,408

 

(476

)

Deferred income taxes

 

16,944

 

(1,616

)

Other accrued liabilities

 

2,718

 

(2,266

)

Net cash provided by (used in) operating activities

 

(12,830

)

41,320

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Investments in property, plant and equipment

 

(25,763

)

(16,974

)

Acquisition of intangible assets

 

 

(4,833

)

Acquisition of business, net of cash received

 

 

(1,661

)

Net cash used in investing activities

 

(25,763

)

(23,468

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments of short-term borrowings

 

 

(7,000

)

Repurchases of common shares

 

(6,116

)

 

Proceeds from issuance of shares

 

2,044

 

2,905

 

Net cash used in financing activities

 

(4,072

)

(4,095

)

Change in cash and cash equivalents

 

(42,665

)

13,757

 

Cash and cash equivalents at beginning of period

 

70,678

 

56,921

 

Cash and cash equivalents at end of period

 

$

28,013

 

$

70,678

 

 

7



 

XYRATEX LTD

SUPPLEMENTAL INFORMATION

 

 

 

Three Months Ended

 

Year Ended

 

 

 

November 30,

 

November 30,

 

November 30,

 

November 30,

 

 

 

2008

 

2007

 

2008

 

2007

 

 

 

(US dollars in thousands, except
per share amounts)

 

(US dollars in thousands, except
per share amounts)

 

 

 

 

 

 

 

 

 

 

 

Summary Reconciliation Of GAAP Net Income To Non-GAAP Net Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

 

$

(55,747

)

$

11,727

 

$

(47,909

)

$

28,109

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

1,223

 

2,485

 

4,882

 

7,304

 

Impairment of goodwill

 

34,256

 

 

34,256

 

 

Equity compensation

 

1,755

 

2,237

 

7,646

 

8,057

 

Other income

 

 

 

 

(890

)

Tax effect of impairment of goodwill

 

(9,592

)

 

(9,592

)

 

Tax effect of other non-GAAP adjustments

 

(1,024

)

(1,602

)

(3,791

)

(4,050

)

Valuation allowance against UK deferred tax asset

 

29,466

 

 

29,466

 

 

Effect on deferred tax of changes to UK tax rates and exchange rates

 

110

 

(1,743

)

1,254

 

(1,040

)

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income

 

$

447

 

$

13,104

 

$

16,212

 

$

37,490

 

 

 

 

 

 

 

 

 

 

 

Summary Reconciliation Of Diluted GAAP Earnings Per Share To Diluted Non-GAAP Earnings Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted GAAP earnings (loss) per share

 

$

(1.92

)

$

0.39

 

$

(1.64

)

$

0.94

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

 

0.04

 

 

0.08

 

 

0.17

 

 

0.24

 

Impairment of goodwill

 

 

1.18

 

 

 

 

1.17

 

 

 

Equity compensation

 

 

0.06

 

 

0.08

 

 

0.26

 

 

0.27

 

Other income

 

 

 

 

 

 

 

 

(0.03

)

Tax effect of impairment of goodwill

 

 

(0.33

)

 

 

(0.33

)

 

Tax effect of other non-GAAP adjustments

 

 

(0.03

)

 

(0.05

)

 

(0.13

)

 

(0.14

)

Valuation allowance against UK deferred tax asset

 

 

1.01

 

 

 

 

1.01

 

 

 

Effect on deferred tax of changes to UK tax rates and exchange rates

 

 

 

 

(0.06

)

 

0.04

 

 

(0.03

)

 

 

 

 

 

 

 

 

 

 

Diluted non-GAAP earnings per share

 

$

0.02

 

$

0.44

 

$

0.56

 

$

1.26

 

 

 

 

 

 

 

 

 

 

 

Summary Of Equity Compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

277

 

356

 

1,264

 

1,238

 

Research and development

 

567

 

711

 

2,469

 

2,477

 

Selling, general and administrative

 

911

 

1,170

 

3,913

 

4,342

 

 

 

 

 

 

 

 

 

 

 

Total equity compensation

 

1,755

 

2,237

 

7,646

 

8,057

 

 

8



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

XYRATEX LTD

 

 

(Registrant)

 

 

 

 

 

 

 

 

Date: February 17, 2009

 

By:

/s/ Richard Pearce

 

 

 

Name: Richard Pearce

 

 

 

Title: Chief Financial Officer

 

9